OPTIMIZE
A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients With Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Arms / Cohorts
Experimental:Regimen A (MAC): Busulfan and Fludarabine, PBSC HCT; Reduce Dose PTCy
Accepting patients
Experimental:Regimen B (MAC): Fludarabine and TBI, PBSC HCT; Reduce Dose PTCy
Accepting patients
Experimental:Regimen C (RIC): Fludarabine and Busulfan; PBSCT HCT; Reduced Dose PTCy
Accepting patients
Experimental:Regimen D (RIC): Fludarabine and Melphalan; PBSCT HCT; Reduced Dose PTCy
Accepting patients
Experimental:Regimen E (NMA): Fludarabine, Cyclophosphamide, and TBI; PBSCT HCT; Reduced Dose PTCy
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.